Team:Slovenia/Conclusions
From 2008.igem.org
(Difference between revisions)
Line 174: | Line 174: | ||
<ul> | <ul> | ||
<li>Chimeric flagellins were produced in bacteria, purified and characterized</li> | <li>Chimeric flagellins were produced in bacteria, purified and characterized</li> | ||
- | <li>Engineered flagellins activate TLR5 as opposed to the native <i>H. pylori</i> flagellin</li> | + | <li>Engineered <i>H. pylori</i> flagellins activate TLR5 as opposed to the native <i>H. pylori</i> flagellin</li> |
<li>Three different implementations of chimeric flagellin vaccines were prepared</li> | <li>Three different implementations of chimeric flagellin vaccines were prepared</li> | ||
<li>Chimeric flagellin is localized at the bacterial surface</li> | <li>Chimeric flagellin is localized at the bacterial surface</li> | ||
- | <li>DNA construct based on chimeric flagellin | + | <li>DNA construct based on chimeric flagellin causes transactivation of TLR5 on neighboring cells (demonstration of the <b>feasibility of introduction of DNA into the epithelial cells to activate the underlying dendritic cells)</b></li> |
</ul> | </ul> | ||
</li> | </li> |
Revision as of 00:57, 30 October 2008
|
|
| |
|
|
Achievements
What remains to be done ?
Prospects
|
|
|